Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental hepatitis c vaccine enters first human tests

NCT ID NCT07237282

First seen Nov 19, 2025 · Last updated May 17, 2026 · Updated 19 times

Summary

This early-stage study tests a new vaccine designed to protect against hepatitis C virus (HCV). The main goal is to check the vaccine's safety and see how well it triggers the body's immune system to produce antibodies. The study will involve 27 healthy adults aged 18 to 45 who do not smoke. Participants will receive injections in the arm and be monitored for side effects and immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ottawa Hospital - General Campus

    Ottawa, Ontario, K1H 8L6, Canada

    Contact

  • Toronto General Hospital - Toronto Centre for Liver Disease

    Toronto, Ontario, M5G 2C4, Canada

    Contact

  • University of Alberta Hospital

    Edmonton, Alberta, T6G 2B7, Canada

    Contact

Conditions

Explore the condition pages connected to this study.